32.81
1.64 (5.26%)
| Penutupan Terdahulu | 31.17 |
| Buka | 31.15 |
| Jumlah Dagangan | 1,186,212 |
| Purata Dagangan (3B) | 1,799,054 |
| Modal Pasaran | 2,006,266,752 |
| Harga / Jualan (P/S) | 4.94 |
| Harga / Buku (P/B) | 4.02 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 2 Feb 2026 |
| Margin Keuntungan | -54.98% |
| Margin Operasi (TTM) | -44.79% |
| EPS Cair (TTM) | -3.25 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 23.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 18.25% |
| Nisbah Semasa (MRQ) | 4.51 |
| Aliran Tunai Operasi (OCF TTM) | -56.11 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -16.89 M |
| Pulangan Atas Aset (ROA TTM) | -15.04% |
| Pulangan Atas Ekuiti (ROE TTM) | -38.22% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menaik | Bercampur |
| Diagnostics & Research (Global) | Menaik | Bercampur | |
| Stok | Twist Bioscience Corporation | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | -4.0 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.40 |
|
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.98% |
| % Dimiliki oleh Institusi | 115.15% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Edgepoint Investment Group Inc. | 30 Sep 2025 | 4,082,319 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 42.00 (Evercore ISI Group, 28.01%) | Beli |
| Median | 41.00 (24.96%) | |
| Rendah | 37.00 (Barclays, 12.77%) | Beli |
| Purata | 40.00 (21.91%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 29.21 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Barclays | 17 Nov 2025 | 37.00 (12.77%) | Beli | 26.46 |
| 02 Oct 2025 | 40.00 (21.91%) | Beli | 30.68 | |
| Stephens & Co. | 04 Nov 2025 | 41.00 (24.96%) | Beli | 30.06 |
| Evercore ISI Group | 07 Oct 2025 | 42.00 (28.01%) | Beli | 31.12 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| WERNER ROBERT F. | - | 29.33 | -822 | -24,109 |
| Jumlah Keseluruhan Kuantiti Bersih | -822 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -24,109 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 29.33 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| WERNER ROBERT F. | Pegawai | 24 Nov 2025 | Jual (-) | 822 | 29.33 | 24,109 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Dec 2025 | Pengumuman | Twist Bioscience Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics Research |
| 14 Nov 2025 | Pengumuman | Twist Bioscience Announces Fiscal 2025 Fourth Quarter and Full Year Financial Results |
| 04 Nov 2025 | Pengumuman | Twist Bioscience to Present at 7th Annual Wolfe Research Healthcare Conference |
| 03 Nov 2025 | Pengumuman | Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) |
| 23 Oct 2025 | Pengumuman | Twist Bioscience to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results on Friday, November 14, 2025 |
| 06 Oct 2025 | Pengumuman | Twist Bioscience and Element Biosciences Advance Collaboration with Launch of New Trinity Freestyle™ Sequencing Workflow for the AVITI™ System |
| 02 Oct 2025 | Pengumuman | Twist Bioscience Announces Publication in Science Examining Biosecurity Screening Practices in AI-assisted Protein Design |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |